ICD-10-CM code · FY2027
E78.8 Other disorders of lipoprotein metabolism
Header codeNot billable: use one of the 2 billable codes below
About E78.8
EvidencePulse™by 2 Minute Medicine®
Go deeper into hyperlipidemia.
Ask about the latest evidence, the landmark trials or what guidelines recommend, with every study cited. No ads, no sponsored answers.
Coding notes for E78.8
No notes of its own; the notes below apply from the codes above it.
Also applies, from E78 Disorders of lipoprotein metabolism and other lipidemias
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Block E70-E88 notes (apply to every code in it)
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- Ehlers-Danlos syndromes (Q79.6-)
Chapter 4 notes (apply to every code in it)
Note
- All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.
Codes under E78.8 2
Related codes in E78
- E78.0 Pure hypercholesterolemiaHeader
- E78.1 Pure hyperglyceridemiaBillable
- E78.2 Mixed hyperlipidemiaBillable
- E78.3 HyperchylomicronemiaBillable
- E78.4 Other hyperlipidemiaHeader
- E78.5 Hyperlipidemia, unspecifiedBillable
- E78.6 Lipoprotein deficiencyBillable
- E78.7 Disorders of bile acid and cholesterol metabolismHeader
- E78.9 Disorder of lipoprotein metabolism, unspecifiedBillable
Latest research on hyperlipidemia
- Statin use after but not before breast cancer diagnosis is associated with improved mortality in hormone receptor-positive early breast cancer
- Statins do not increase breast cancer risk in postmenopausal women
- Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
- Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
- Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis
Landmark trials from 2MM Classics
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plansICD-10-CM FY2027 code set, as published by the CDC National Center for Health Statistics (NCHS) and CMS, effective October 1, 2026 to September 30, 2027. Codes, titles and notes are shown as published. Check payer rules and the official guidelines before billing. This page is not medical advice.
Get the app